Learning Objectives
This webinar is to inform and educate interventional cardiologists and cardiac surgeons on:
- The characteristics of AF-associated stroke
- The missed opportunity for 7000 people every year whose stroke could have been prevented by anticoagulation
- The Oral Direct Inhibitors (ODI), which afford alternatives to warfarin
- The myths and realities about ODI
Key references:
- ROCKET AF study
- RELY study
- ARISTOLE study
- AVERROES study
- NICE TA 249 Dabigatran for AF
- NICE TA 256 Rivaroxaban for AF
- NICE TA 275 Apixaban for AF
